All In Biotech

Drug Trial Radar · NCT05869643

A Clinical Trial of STP0404 in Adults With HIV-1 Infection

A Phase 2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Investigate the Antiviral Effect, Safety, Tolerability, and Pharmacokinetics of STP0404 in Adults With HIV-1 Infection

Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

May 23, 2023

Primary completion

Apr 25, 2026

Study completion May 6, 2026

Sponsor

Lead sponsor
ST Pharm Co., Ltd.Industry
Sponsor type
Industry
First posted
May 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in adult participants living with Human Immunodeficiency Virus Type 1 (HIV-1) infection.

Conditions

  • HIV-1-infection

Interventions

  • Low-dose STP0404 (Pirmitegravir)Drug

    Once daily, oral capsule taken after breakfast

  • Medium-dose STP0404 (Pirmitegravir)Drug

    Once daily, oral capsule taken after breakfast

  • High-dose STP0404 (Pirmitegravir)Drug

    Once daily, oral capsule taken after breakfast

  • PlaceboDrug

    Matching placebo capsule, taken orally once daily after breakfast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HIV-1 RNA copies change in plasmaTime frame: Day 1, Day 11
  2. Total Number of Adverse Events (AEs) occurring through Day 11Time frame: Through day 11
  3. Total Number of Serious Adverse Events (SAEs) occurring through Day 11Time frame: Through day 11
  4. Mean area under the concentration-time curve from zero to 24 hours (AUC0-24h)Time frame: Day 1, Day 10
  5. Mean observed maximum concentration after administration (Cmax)Time frame: Day 1, Day 10
  6. Mean time to reach Cmax (Tmax)Time frame: Day 1, Day 10
  7. Mean observed concentration at 24 hours after administration (C24h)Time frame: Day 2, Day 4, Day 7, Day10, Day 11
  8. Mean area under the concentration-time curve to infinite time (AUCinf)Time frame: Day 10
  9. Mean area under the concentration-time curve to time t (AUCt)Time frame: Day 10
  10. Mean terminal half-life (t1/2)Time frame: Day 10
  11. Mean apparent oral clearance (CL/F)Time frame: Day 10
  12. Mean apparent volume of distribution (Vd/F)Time frame: Day 10

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Kaiser Permenente Los Angeles Medical Center

    Los Angeles, California

  • Ruane Clinical Research, Inc.

    Los Angeles, California

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • Schiff Center for Liver Diseases/University of Miami

    Miami, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • USF Health South Tampa Center for Advanced Healthcare

    Tampa, Florida

  • Be Well Medical Center

    Berkley, Michigan

  • Saint Michael's Medical Center

    Newark, New Jersey

  • South Jersey Infectious Disease

    Somers Point, New Jersey

  • North Shore University Hospital

    Manhasset, New York

  • Atrium Health Wake Forest Baptist Medical Center - PPDS

    Winston-Salem, North Carolina

  • St Hope Foundation, Inc

    Bellaire, Texas

  • North Texas Infectious Diseases Consultants, P.A.

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.